2Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase,in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA,2003,290(16): 2149-2158.
3Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ,1995,311(7010): 899-909.
4Therasse P, Arbuck SC-, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Ca
5Heimberger AB, Learn CA, Archer GE, et al. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). Clin Cancer Res,2002,8(11) : 3496-3502.
6Cappuzzo F, Ardizzoni A, Soto-Parra H, et al. Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC).Lung Cancer,2003,41(2) : 227-231.
7Katakami N, Okazaki M, Kinose D, et al. A retrospective analysis of the outcome of patients (pts) in advanced recurrent adenocarcinoma of the lung who have received gefitinib after treatment of platinum-base regimen. Proc Am Soc Clin Oncol,2003,22: 666a.
8Tamura K, Yamamoto N, Takeda K, et al. Am epidemiological survey for interstitial lung disease induced by gefitinib in patients with advanced non-small cell lung cancer. West Japan Thoracic Oncology Group (WJTOG). Eur J Cancer, 2003, 1 (5 Suppl) :S21.
9Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors:results of a phase Ⅰ trial. J Clin Oncol,2002,20(9): 2240-225
10Bernardo G, Cuzzoni Q, Strada MR, et al. First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: a phase Ⅱ study. Cancer Invest,2002,20(3): 293-302.
5Gutiérrez-Valencia Enrique,Sánchez-Rodríguez Irving,Balderrama-Ibarra Ricardo,Fuentes-LaraJesús,Rios-Martínez Alan,Vázquez Aldana Arroyo Iñigo,Bayardo-López Luis,Hernández ChávezAllan,Puebla-Mora Ana Graciela,Nader-Roa Liliana,Espíritu-Rodríguez Roque.Diagnosis and management of brain metastases:an updated review from a radiation oncology perspective[J].Journal of Cancer Metastasis and Treatment,2019,4(7):12-27.
